Brigitte Dreno
Expertise in
22
conditions

Brigitte Dreno

Nantes, FR 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
22
conditions
Nantes, FR 

Overview

Brigitte Dreno practices practicing medicine in Nantes, France.

Ms. Dreno is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Acne, Melanoma, Comedones, Melasma, and Lymphadenectomy.

She is actively involved in clinical research, co-authoring 529 peer reviewed articles and participating in 12 clinical trials.

Gender

Female

Locations

Nantes, France
Other Locations
Tours, France
Montpellier, 34295, France
Grenoble, France
Grand, France
CHU d'Amiens Picardie Site Nord
Amiens, 80080, France
89, Rue D'Assas, Paris, 75005, France
Annecy, France
Place Alexis Ricordeau 44093 Nantes Cedex 1, Place, 44093, France
Angers, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

French National Cohort of Patients With Melanoma (Any Stage). Network for Research and Clinical Investigation, the RIC-Mel Network.
French National Cohort of Patients With Melanoma (Any Stage). Network for Research and Clinical Investigation, the RIC-Mel Network.
Enrollment Status: Recruiting
Publish Date: July 22, 2025
Constitution of a National Cohort of Patients With Metastatic Melanoma Resectable Stage II or Stage III or IV or Unresectable Primary With the Objective of Setting up Epidemiological Monitoring and Clinico-biological Database, MELBASE
Constitution of a National Cohort of Patients With Metastatic Melanoma Resectable Stage II or Stage III or IV or Unresectable Primary With the Objective of Setting up Epidemiological Monitoring and Clinico-biological Database, MELBASE
Enrollment Status: Recruiting
Publish Date: February 11, 2025
Intervention Type: Other
Written Advice to Improve Compliance With Early Detection of Melanoma in First-degree Relatives: a Multicenter, Cluster-randomized Intervention Trial to Evaluate the Impact of Specific Incentives and Study Psychological Determinants of Early Melanoma Detection Behavior in First-degree Relatives
Written Advice to Improve Compliance With Early Detection of Melanoma in First-degree Relatives: a Multicenter, Cluster-randomized Intervention Trial to Evaluate the Impact of Specific Incentives and Study Psychological Determinants of Early Melanoma Detection Behavior in First-degree Relatives
Enrollment Status: Completed
Publish Date: December 30, 2025
Intervention Type: Behavioral
Study Phase: Not Applicable
A Phase 1, Open-Label, Dose-Escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 in Melanoma Patients Receiving Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes
A Phase 1, Open-Label, Dose-Escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 in Melanoma Patients Receiving Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes
Enrollment Status: Completed
Publish Date: August 07, 2025
Intervention Type: Biological
Study Drug: TILT-123
Study Phase: Phase 1
Randomized Double-blind Study on the Benefit of Spironolactone for Treating Acne of Adult Woman.
Randomized Double-blind Study on the Benefit of Spironolactone for Treating Acne of Adult Woman.
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Drug
Study Drugs: Spironolactone, Doxycycline
Study Phase: Phase 3
Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face
Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face
Enrollment Status: Completed
Publish Date: December 06, 2022
Intervention Type: Drug
Study Drugs: Imiquimod Cream+Surgery, Surgery
Study Phase: Phase 3
Restauration of EBV Control in SLE Phase 1-2 Trial Evaluating Adoptive Transfer of Autologous EBV- Specific Cytotoxic T Lymphocytes in SLE Treatment
Restauration of EBV Control in SLE Phase 1-2 Trial Evaluating Adoptive Transfer of Autologous EBV- Specific Cytotoxic T Lymphocytes in SLE Treatment
Enrollment Status: Terminated
Publish Date: March 25, 2022
Intervention Type: Biological
Study Drug: Autologous EBV specific CTL infusion
Study Phase: Phase 1/Phase 2
PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Enrollment Status: Terminated
Publish Date: January 19, 2022
Intervention Type: Drug
Study Phase: Phase 3
An Exploratory Study to Assess the Efficacy of the Avène Hydrotherapy on Chronic Pruritus in Adults With Plaque Psoriasis
An Exploratory Study to Assess the Efficacy of the Avène Hydrotherapy on Chronic Pruritus in Adults With Plaque Psoriasis
Enrollment Status: Completed
Publish Date: April 02, 2021
Intervention Type: Other
Study Phase: Not Applicable
Evaluation of Cobimetinib + Vemurafenib Combination Treatment in Patients With Brain Metastasis BRAFV600 Mutated Cutaneous Melanoma
Evaluation of Cobimetinib + Vemurafenib Combination Treatment in Patients With Brain Metastasis BRAFV600 Mutated Cutaneous Melanoma
Enrollment Status: Completed
Publish Date: January 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

529 Total Publications

Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.
Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.
Journal: Journal for immunotherapy of cancer
Published: July 27, 2026

Frequently Asked Questions about Brigitte Dreno

Is Brigitte Dreno a top-rated expert for Acne?

MediFind is an objective health platform that identifies experts based on real-world data. Brigitte Dreno is classified as an Elite expert for Acne, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Brigitte Dreno participate in research or clinical trials?

Yes. Brigitte Dreno has published 529 articles and abstracts on conditions like Acne. You can view a list of Brigitte Dreno's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Dreno's expertise for a condition
ConditionClose
View All 14 Advanced Conditions
View All 37 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile